IGF1 and cardiac hypertrophy: The current findings are comparable with the results from a previous study which reported that OA activates insulin receptor-1 (IR-1) which lowers circulating insulin and IGF-1 levels and subsequently reduces cardiac hypertrophy in animal models of obesity and metabolic syndrome [50].